ストックスクリーナーアプリを入手
12.33
6.20%
0.72
アフターアワーズ：
12.33
前日終値:
$11.61
開ける：
$11.7
24時間の取引高:
107.27K
Relative Volume:
0.61
時価総額：
$177.83M
収益：
$6.39M
当期純損益:
$-117.26M
株価収益率:
-0.9879
EPS:
-12.4807
ネットキャッシュフロー:
$-79.08M
1週間 パフォーマンス:
+34.75%
1か月 パフォーマンス:
-4.34%
6か月 パフォーマンス:
+123.37%
1年 パフォーマンス:
-10.65%
1日の値動き範囲:
$11.69
$12.67
1週間の範囲:
$9.12
$12.67
52週間の値動き範囲:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
12.33 | 167.45M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-11-13 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | ダウングレード | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-10 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Raymond James | Strong Buy |
| 2024-08-14 | 開始されました | William Blair | Outperform |
| 2024-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-02-27 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-29 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-10 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-01-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 開始されました | B. Riley Securities | Buy |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 開始されました | Cowen | Outperform |
| 2019-10-28 | 開始されました | Goldman | Buy |
| 2019-10-28 | 開始されました | JP Morgan | Overweight |
すべてを表示
Korro Bio Inc (KRRO) 最新ニュース
Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli
Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser
Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 - Minichart
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Korro Bio stock price target on financing impact By Investing.com - Investing.com South Africa
Korro Bio nominates new candidate for AATD - BioWorld News
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein - Traders Union
H.C. Wainwright cuts Korro Bio stock price target on financing impact - Investing.com Nigeria
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency - TipRanks
Korro Bio adds AATD treatment candidate to pipeline - Investing.com
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN
KRRO Initiates Coverage by Citigroup -- Announces Buy Rating - GuruFocus
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com
Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Stock Picks - Newser
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan
TradingKey - TradingKey
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro announces oversubscribed $85 million private placement - MSN
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo
Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa
Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Korro Bio IncReports No Collaboration Reve - Moomoo
Korro Bio (KRRO) trims R&D spend and boosts cash to $157M - Stock Titan
Korro Bio, Inc. 1Q 2026: Revenue $0M, EPS $(1.69) — 10-Q Summary - TradingView
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Korro raises $85M, targets 2026 filing for rare-disease drug - Stock Titan
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan
What Korro Bio (KRRO) management is not saying enough about (Technical Strength) 2026-05-06Top Trending Breakouts - newser.com
Korro CEO and top executives line up two investor fireside chats - Stock Titan
Korro to Participate in Upcoming Investor Conferences - marketscreener.com
Korro Bio executives to present at two major investor conferences in May 2026 - Pluang
Korro Bio Inc expected to post a loss of $1.84 a shareEarnings Preview - TradingView
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
Korro Bio (KRRO) to Release Quarterly Earnings on Wednesday - MarketBeat
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock - Yahoo Finance Australia
Korro Bio Inc (KRRO) 財務データ
収益
当期純利益
現金流量
EPS
Korro Bio Inc (KRRO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Yang Rick | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| SANDELL SCOTT D | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| New Enterprise Associates 17, | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Chang Carmen | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| BASKETT FOREST | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Mathers Edward T | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Makhzoumi Mohamad | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Walker Paul Edward | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Florence Anthony A. Jr. | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):